Research & Literature

Car Crashes and Central Disorders of Hypersomnolence: A French Study.

Pizza F, Jaussent I, Lopez R, et al.

PloS one 2015; (10(6)):e0129386 doi:10.1371/journal.pone.0129386.

What Does One Sleep-Onset REM Period—During Either Nocturnal Polysomnography or Multiple Sleep Latency Test—Mean in Differential Diagnosis of Central Hypersomnias?

Bozluolcay M, Nalbantoglu M, Benbir Senel G, Karadeniz D

Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society 2015; (32(4)):364-8 doi:10.1097/WNP.0000000000000192.

An association analysis of HLA-DQB1 with narcolepsy without cataplexy and idiopathic hypersomnia with/without long sleep time in a Japanese population.

Miyagawa T, Toyoda H, Kanbayashi T, et al.

Human genome variation 2015; (2()):15031 doi:10.1038/hgv.2015.31.

Treatment Options for Narcolepsy.

Barateau L, Lopez R, Dauvilliers Y

CNS drugs 2016; (30(5)):369-79 doi:10.1007/s40263-016-0337-4.

The ICSD-3 and DSM-5 guidelines for diagnosing narcolepsy: clinical relevance and practicality.

Ruoff C, Rye D

Current medical research and opinion 2016; (32(10)):1611-1622 doi:10.1080/03007995.2016.1208643.

Management of Narcolepsy.

Barateau L, Lopez R, Dauvilliers Y

Current treatment options in neurology 2016; (18(10)):43 doi:10.1007/s11940-016-0429-y.

Urine Toxicology in Adults Evaluated for a Central Hypersomnia and How the Results Modify the Physician's Diagnosis.

Kosky CA, Bonakis A, Yogendran A, et al.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2016; (12(11)):1499-1505 doi:10.5664/jcsm.6276.

Impact of sodium oxybate, modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy.

Black J, Swick T, Bogan R, et al.

Sleep medicine 2016; (24()):57-62 doi:10.1016/j.sleep.2016.07.010.

French consensus. Idiopathic hypersomnia: Investigations and follow-up.

Leu-Semenescu S, Quera-Salva MA, Dauvilliers Y

Revue neurologique 2017; (173(1-2)):32-37 doi:10.1016/j.neurol.2016.09.015.

Test-Retest Reliability of the Multiple Sleep Latency Test in Central Disorders of Hypersomnolence.

Lopez R, Doukkali A, Barateau L, et al.

Sleep 2017; (40(12)) doi:10.1093/sleep/zsx164.

A Longitudinal Follow-Up Study on Multiple Sleep Latency Test and Body Mass Index of Patients With Narcolepsy Type 1 in Korea.

Um YH, Kim TW, Jeong JH, et al.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2017; (13(12)):1441-1444 doi:10.5664/jcsm.6844.

The MSLT is Repeatable in Narcolepsy Type 1 But Not Narcolepsy Type 2: A Retrospective Patient Study.

Ruoff C, Pizza F, Trotti LM, et al.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2018; (14(1)):65-74 doi:10.5664/jcsm.6882.

The distinguishing motor features of cataplexy: a study from video-recorded attacks.

Pizza F, Antelmi E, Vandi S, et al.

Sleep 2018; (41(5)) doi:10.1093/sleep/zsy026.

Multiple sleep latency test in narcolepsy type 1 and narcolepsy type 2: A 5-year follow-up study.

Huang YS, Guilleminault C, Lin CH, et al.

Journal of sleep research 2018; (27(5)):e12700 doi:10.1111/jsr.12700.

A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor.

Carter LP, Henningfield JE, Wang YG, et al.

Journal of psychopharmacology (Oxford, England) 2018; (32(12)):1351-1361 doi:10.1177/0269881118796814.

Maintenance of Wakefulness Test, real and simulated driving in patients with narcolepsy/hypersomnia.

Sagaspe P, Micoulaud-Franchi JA, Coste O, et al.

Sleep medicine 2019; (55()):1-5 doi:10.1016/j.sleep.2018.02.009.

Single-Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End-Stage Renal Disease Requiring Hemodialysis.

Zomorodi K, Chen D, Lee L, et al.

Journal of clinical pharmacology 2019; (59(8)):1120-1129 doi:10.1002/jcph.1402.

Residual excessive daytime sleepiness in patients with obstructive sleep apnea treated with positive airway pressure therapy.

Foster SN, Hansen SL, Scalzitti NJ, et al.

Sleep & breathing = Schlaf & Atmung 2020; (24(1)):143-150 doi:10.1007/s11325-019-01830-6.

Comorbid psychiatric disorders among patients with narcolepsy.

Alasim H, AlQazlan S, Albanyan S, et al.

Sleep & breathing = Schlaf & Atmung 2020; (24(2)):629-636 doi:10.1007/s11325-019-01890-8.

Narcolepsy - clinical spectrum, aetiopathophysiology, diagnosis and treatment.

Bassetti CLA, Adamantidis A, Burdakov D, et al.

Nature reviews. Neurology 2019; (15(9)):519-539 doi:10.1038/s41582-019-0226-9.

Transgenic Archaerhodopsin-3 Expression in Hypocretin/Orexin Neurons Engenders Cellular Dysfunction and Features of Type 2 Narcolepsy.

Williams RH, Tsunematsu T, Thomas AM, et al.

The Journal of neuroscience : the official journal of the Society for Neuroscience 2019; (39(47)):9435-9452 doi:10.1523/JNEUROSCI.0311-19.2019.

Treatment of Excessive Daytime Sleepiness in Patients with Narcolepsy.

Pérez-Carbonell L

Current treatment options in neurology 2019; (21(11)):57 doi:10.1007/s11940-019-0595-9.

Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects.

Sousa A, Dinis-Oliveira RJ

Substance abuse 2020; (41(2)):155-173 doi:10.1080/08897077.2019.1700584.

Utility of the sleep stage sequence preceding sleep onset REM periods for the diagnosis of narcolepsy: a study in a Japanese cohort.

Kawai R, Watanabe A, Fujita S, et al.

Sleep medicine 2020; (68()):9-17 doi:10.1016/j.sleep.2019.04.008.

Update on Persistent Excessive Daytime Sleepiness in OSA.

Javaheri S, Javaheri S

Chest 2020; (158(2)):776-786 doi:10.1016/j.chest.2020.02.036.

Advance taper of antidepressants prior to multiple sleep latency testing increases the number of sleep-onset rapid eye movement periods and reduces mean sleep latency.

Kolla BP, Jahani Kondori M, Silber MH, et al.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2020; (16(11)):1921-1927 doi:10.5664/jcsm.8738.

New pharmacologic agents for insomnia and hypersomnia.

Earl DC, Van Tyle KM

Current opinion in pulmonary medicine 2020; (26(6)):629-633 doi:10.1097/MCP.0000000000000722.

Narcolepsy type 2: A rare, yet existing entity.

Baumann-Vogel H, Schreckenbauer L, Valko PO, et al.

Journal of sleep research 2021; (30(3)):e13203 doi:10.1111/jsr.13203.

Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy.

Bogan RK, Thorpy MJ, Dauvilliers Y, et al.

Sleep 2021; (44(3)) doi:10.1093/sleep/zsaa206.

Therapeutic Strategies for Mitigating Driving Risk in Patients with Narcolepsy.

McCall CA, Watson NF

Therapeutics and clinical risk management 2020; (16()):1099-1108 doi:10.2147/TCRM.S244714.

γ-Hydroxybutyric Acid: Pharmacokinetics, Pharmacodynamics, and Toxicology.

Felmlee MA, Morse BL, Morris ME

The AAPS journal 2021; (23(1)):22 doi:10.1208/s12248-020-00543-z.

On-the-road driving performance of patients with central disorders of hypersomnolence.

van der Sluiszen NNJJM, Urbanus B, Lammers GJ, et al.

Traffic injury prevention 2021; (22(2)):120-126 doi:10.1080/15389588.2020.1862804.

Diagnosing narcolepsy in the active duty military population.

Villarreal B, Powell T, Brock MS, Hansen S

Sleep & breathing = Schlaf & Atmung 2021; (25(2)):995-1002 doi:10.1007/s11325-020-02163-5.

The influence of antidepressants and actigraphy-derived sleep characteristics on pediatric multiple sleep latency testing.

Mansukhani MP, Dhankikar S, Kotagal S, Kolla BP

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2021; (17(11)):2179-2185 doi:10.5664/jcsm.9338.

European guideline and expert statements on the management of narcolepsy in adults and children.

Bassetti CLA, Kallweit U, Vignatelli L, et al.

Journal of sleep research 2021; (30(6)):e13387 doi:10.1111/jsr.13387.

Actigraphy prior to Multiple Sleep Latency Test: nighttime total sleep time predicts sleep-onset latency.

Kelly MR, Zeidler MR, DeCruz S, et al.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2022; (18(1)):161-170 doi:10.5664/jcsm.9528.

Recommended protocols for the Multiple Sleep Latency Test and Maintenance of Wakefulness Test in adults: guidance from the American Academy of Sleep Medicine.

Krahn LE, Arand DL, Avidan AY, et al.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2021; (17(12)):2489-2498 doi:10.5664/jcsm.9620.

Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline.

Maski K, Trotti LM, Kotagal S, et al.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2021; (17(9)):1881-1893 doi:10.5664/jcsm.9328.

Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia.

Junnarkar G, Allphin C, Profant J, et al.

Expert opinion on drug discovery 2022; (17(2)):109-119 doi:10.1080/17460441.2022.1999226.

Differential characteristics of repeated polysomnography and multiple sleep latency test parameters in narcolepsy type 1 and type 2 patients: a longitudinal retrospective study.

Um YH, Oh J, Kim SM, et al.

Sleep & breathing = Schlaf & Atmung 2022; (26(4)):1939-1946 doi:10.1007/s11325-021-02525-7.

Comparative polysomnography parameters between narcolepsy type 1/type 2 and idiopathic hypersomnia: A systematic review and meta-analysis.

Zhang Y, Ren R, Yang L, et al.

Sleep medicine reviews 2022; (63()):101610 doi:10.1016/j.smrv.2022.101610.

Calcium, Magnesium, Potassium and Sodium Oxybates (Xywav®) in Sleep Disorders: A Profile of Its Use.

Heo YA

CNS drugs 2022; (36(5)):541-549 doi:10.1007/s40263-022-00912-6.

Usefulness of the maintenance of wakefulness test in central disorders of hypersomnolence: a scoping review.

Bijlenga D, Overeem S, Fronczek R, Lammers GJ

Sleep 2022; (45(8)) doi:10.1093/sleep/zsac091.

Intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: their significance in the diagnosis of narcolepsy type 1.

van der Hoeven AE, Fronczek R, Schinkelshoek MS, et al.

Sleep 2022; (45(5)) doi:10.1093/sleep/zsac052.

Acute Sodium Oxybate Intoxication: A Case Report and Review of the Literature.

Drevin G, Briet M, Ferec S, et al.

Therapeutic drug monitoring 2023; (45(2)):277-281 doi:10.1097/FTD.0000000000001011.

Repeated polysomnography and multiple sleep latency test in narcolepsy type 1 and other hypersomnolence disorders.

Torstensen EW, Haubjerg Østerby NC, Kornum BR, et al.

Sleep medicine 2023; (110()):91-98 doi:10.1016/j.sleep.2023.07.029.

Narcolepsies, update in 2023.

Barateau L, Pizza F, Chenini S, et al.

Revue neurologique 2023; (179(7)):727-740 doi:10.1016/j.neurol.2023.08.001.

ADHD in narcolepsy: A closer look at prevalence and ties.

Ren J, Zhao X, Su C, et al.

Neuroscience and biobehavioral reviews 2024; (156()):105471 doi:10.1016/j.neubiorev.2023.105471.

Work productivity and activity impairment in patients with narcolepsy type 1.

Bassi C, Biscarini F, Zenesini C, et al.

Journal of sleep research 2024; (33(3)):e14087 doi:10.1111/jsr.14087.

Narcolepsy Severity Scale-2 and Idiopathic Hypersomnia Severity Scale to better quantify symptoms severity and consequences in Narcolepsy type 2.

Barateau L, Chenini S, Denis C, et al.

Sleep 2024; (47(5)) doi:10.1093/sleep/zsad323.

Narcolepsy: an interface among neurology, immunology, sleep, and genetics.

Coelho FMS

Arquivos de neuro-psiquiatria 2024; (82(6)):1-9 doi:10.1055/s-0044-1779299.

High-resolution HLA sequencing and hypocretin receptor 2 autoantibodies in narcolepsy type 1 and type 2.

Hamdan S, Wasling P, Lind A

International journal of immunogenetics 2024; (51(5)):310-318 doi:10.1111/iji.12688.

Cardiovascular Risks in People With Narcolepsy: Expert Panel Consensus Recommendations.

Kwon Y, Gami AS, Javaheri S, et al.

Journal of the American Heart Association 2024; (13(16)):e035168 doi:10.1161/JAHA.124.035168.

Association between human leukocyte antigen class II-DR-DQ and narcolepsy: a case control study.

Bacelar A, Fernandez O, Paradella E, et al.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2024; (20(12)):1945-1953 doi:10.5664/jcsm.11300.

Evaluation of pitolisant, sodium oxybate, solriamfetol, and modafinil for the management of narcolepsy: a retrospective analysis of the FAERS database.

Zhou X, Chen J, Xu B, Chen L

Frontiers in pharmacology 2024; (15()):1415918 doi:10.3389/fphar.2024.1415918.

Quality of life and its associates in narcolepsy 1 and 2 types and idiopathic hypersomnia.

Galušková K, Nevšímalová S, Příhodová I, et al.

Sleep medicine 2025; (129()):31-39 doi:10.1016/j.sleep.2025.02.019.

Rising pressure to understand the risks of hypertension in children with narcolepsy type 1.

Montesano E, Garcia ME, Lyon S, et al.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2025; (21(6)):1081-1091 doi:10.5664/jcsm.11628.

Narcolepsy Is Associated With Subclinical Cardiovascular Disease as Early as Childhood: A Big Data Analysis.

Kaufmann CN, Riaz M, Park H, et al.

Journal of the American Heart Association 2025; (14(12)):e039899 doi:10.1161/JAHA.124.039899.

Narcolepsy and cardiovascular health: A big picture perspective.

Grandner MA, Morse AM, Avidan AY, et al.

Sleep medicine 2025; (133()):106640 doi:10.1016/j.sleep.2025.106640.

Narcolepsy and psychiatric comorbidity: a review of the literature.

Verstraete L, Van Den Bossche M

International journal of clinical and health psychology : IJCHP 2025; (25(2)):100591 doi:10.1016/j.ijchp.2025.100591.

Narcolepsy and risk of cardiovascular outcomes beyond stimulant use.

Riaz M, Bhattacharjee R, Lo-Ciganic W, et al.

Sleep 2025; (48(12)) doi:10.1093/sleep/zsaf197.

Narcolepsy type 2 is an unstable diagnosis and idiopathic hypersomnia has the potential for remission-long-term and cross-sectional observations from the Bern Sleep-Wake Registry.

Cavalli RG, Tamagni AEM, van der Meer J, et al.

Sleep 2026; (49(3)) doi:10.1093/sleep/zsaf242.

Central disorders of hypersomnolence - A narrative review on current and potential biomarkers.

Tai JE, Sivam S, D'Rozario A, et al.

Sleep medicine reviews 2025; (84()):102167 doi:10.1016/j.smrv.2025.102167.

Drug Interactions With Excessive Daytime Sleepiness Treatments.

Thomas SV, Malesker MA, Hilleman DE, Dewan NA

The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians 2025; 87551225251369328 doi:10.1177/87551225251369328.

Effects of High- Versus Low-Sodium Oxybate on Blood Pressure in Patients With Narcolepsy.

White WB, Kovacs RJ, Alexander JK, et al.

Hypertension (Dallas, Tex. : 1979) 2025; (82(12)):2162-2171 doi:10.1161/HYPERTENSIONAHA.125.25730.

Sleep time and SOREMPs features support idiopathic hypersomnia and narcolepsy type 2 as a single disease entity.

Rassu AL, Barateau L, Evangelista E, et al.

Sleep 2026; (49(4)) doi:10.1093/sleep/zsaf378.

Samelisant (SUVN-G3031), a histamine H3 receptor inverse agonist, as a potential treatment for narcolepsy: a phase-2 drug evaluation.

Nirogi R, Shinde A, Subramanian R, et al.

Expert opinion on investigational drugs 2026; (35(3)):203-210 doi:10.1080/13543784.2026.2634990.

Narcolepsy and metabolic disease: A meta-analytic synthesis.

Zhang X, Yin W, Ren J, et al.

Sleep medicine reviews 2026; (87()):102264 doi:10.1016/j.smrv.2026.102264.

Test-retest repeatability of the multiple sleep latency test in non-cataleptic hypersomnolence disorders.

Johnson J, Grigg-Damberger M, El Ahdab J, et al.

Sleep medicine 2026; (142()):108876 doi:10.1016/j.sleep.2026.108876.

Modafinil-associated psychosis: a systematic review of case characteristics and management strategies.

Sato Y, Sakuma A, Tomita H

Therapeutic advances in psychopharmacology 2026; (16()):20451253261446554 doi:10.1177/20451253261446554.

Narcolepsy Type 2 in an Adolescent With Childhood Obstructive Sleep Apnea and Coexisting Absence Epilepsy: A Case Report.

Sahu G, Saini VM, Nair S

Cureus 2026; (18(4)):e107464 doi:10.7759/cureus.107464.

To diagnose narcolepsy type 1 after a negative multiple sleep latency test: the contribution of systematic hypocretin measurement.

Biscarini F, Vandi S, Neccia G, et al.

Sleep 2026; (49(9)) doi:10.1093/sleep/zsag142.

[Pharmacological and non-pharmacological treatment for narcolepsy].

Gorbachev NA, Balabanova MA, Poluektov MG

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 2026; (126(5. Vyp. 2)):55-62 doi:10.17116/jnevro202612605255.

Redefining hypersomnia disorders in the context of psychiatry.

Mignot E

L'Encephale 2026; (52(3S)):S94-S99 doi:10.1016/j.encep.2026.04.001.